Ceptor Announces New Compound Patents Pending For Neurodur In Multiple Sclerosis

Main Category: Multiple Sclerosis
Article Date: 09 Mar 2005 - 9:00 PDT

email to a friend   printer friendly   opinions  

CepTor Corporation (OTC BB: CEPO) announced that intellectual property filings have been made to further strengthen its patent position for the Company's nerve cell targeted protease inhibitor platform technology. More specifically, CepTor has filed to receive an additional 20 years of compound protection for oral delivery of Neurodur with accompanied use protection in multiple sclerosis (MS) and other neurodegenerative diseases.

William Pursley, CepTor's Chairman and CEO stated, "Protecting our property remains a never-ending priority. We are unaware of any other specific nerve cell targeted, protease inhibiting compounds being used or developed to minimize or prevent the degradation of nerve tissue associated with MS and other neurodegenerative diseases. We believe specific targeting provides us the unique benefit of potentially delivering our therapeutic compounds more safely and, in terms of efficacy, more efficiently."

About CepTor Corporation

CepTor Corporation is a biopharmaceutical company focusing on the development of proprietary, cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne's muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy.

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement.

CONTACTS:

Don Fallon, CFO
CepTor Corporation
(410) 527-9998 Fax (410) 527-9867

Andria Arena
Wolfe Axelrod Weinberger Assoc. LLC
(212) 370-4500 Fax (212) 370-4505
andria@wolfeaxelrod.com

• Additional
• References
• Citations